Op poisoning FMT
Reading File
Finding Sources
Finding Sources
Finding Sources
Searching PubMed
organophosphate poisoning fecal microbiota transplantation
Reading File
Reading File
Finding Sources
Searching PubMed
organophosphate poisoning gut microbiome dysbiosis
Reading File
Reading File
Searching PubMed
FMT fecal microbiota transplant pesticide poisoning critical illness
Searching the Web
organophosphate poisoning FMT fecal microbiota transplant clinical evidence 2024 2025
Reading File
Reading File
Searching PubMed
organophosphate poisoning management atropine oxime
Reading Article
Now I have everything needed for a comprehensive answer. Let me synthesize.
Organophosphate (OP) Poisoning - Full Management + Role of FMT
Pathophysiology
OP compounds (diazinon, malathion, parathion, chlorpyrifos, nerve agents) irreversibly inhibit acetylcholinesterase (AChE) via phosphorylation. This prevents breakdown of acetylcholine (ACh), causing it to accumulate at all cholinergic synapses - muscarinic (parasympathetic effectors), nicotinic (NMJ, autonomic ganglia), and CNS sites. The result is a cholinergic crisis. Over time, the OP-AChE bond undergoes "aging" (permanent inactivation), after which oxime therapy is no longer effective.
- Tintinalli's Emergency Medicine, p. Chapter 201
Clinical Toxidrome - Four Syndromes
| Syndrome | Timing | Features |
|---|---|---|
| Acute cholinergic crisis | Within 8-24h | SLUDGE + killer Bs (see below) |
| Intermediate syndrome | 24h-96h after acute phase | Proximal limb weakness, neck flexor weakness, respiratory muscle paralysis - no preceding cholinergic excess |
| Chronic toxicity | Weeks-months | Neuropsychiatric effects |
| OP-induced delayed neuropathy (OPIDN) | 2-3 weeks post-exposure | Distal motor neuropathy |
Muscarinic effects (SLUDGE/DUMBELS):
- Salivation, Lacrimation, Urination, Defecation, GI cramps, Emesis
- Bradycardia, Bronchorrhea, Bronchospasm (the "killer Bs" - primary cause of death), Miosis
Nicotinic effects:
- Muscle fasciculations, weakness, paralysis, tachycardia, hypertension, mydriasis (can mask miosis)
CNS effects:
- Anxiety, seizures, coma, respiratory depression
Management
1. Decontamination
- Remove and destroy clothing (dermal absorption is significant)
- Flush skin thoroughly with water (level C PPE for caregivers - full-face respirator, chemical-resistant suit, nitrile gloves)
- Gastric lavage and activated charcoal are NOT beneficial - cholinergics are rapidly absorbed, and profuse vomiting/diarrhea early in ingestion negates benefit
- The 2026 umbrella review confirms gastric lavage has doubtful efficacy and may be harmful (PMID: 42258859)
2. Airway & Supportive Care
- Death results from airway/respiratory failure - suction secretions, oxygenate, ventilate
- Succinylcholine for RSI has prolonged effect (4-6 hours) due to cholinesterase inhibition - prefer rocuronium 1 mg/kg (non-depolarizing, not metabolized by cholinesterases)
- Treat seizures with atropine + benzodiazepines
3. Atropine - the mainstay antidote
- Competitive antagonist at muscarinic receptors (does not reverse nicotinic/NMJ effects)
- Triggers: pinpoint pupils, bronchorrhea, respiratory distress, excessive secretions
- Initial dose (adult): 1.2-3.0 mg IV, doubled every 5 minutes until:
- Chest clear on auscultation
- HR >80 bpm
- SBP >80 mmHg
- Note: Pupillary dilation is NOT a therapeutic endpoint; tachycardia is NOT a contraindication
- Massive doses (hundreds of mg) may be needed in severe ingestions
- Once adequate atropinization achieved, start infusion at 10-20% of the loading dose per hour
- Atropine reduces secretions but does NOT reverse muscle weakness - ventilation still required
4. Pralidoxime (2-PAM) - oxime therapy
- Displaces OP from AChE active site, reactivating the enzyme - reverses muscarinic, nicotinic, AND CNS effects
- Critical: must be given before aging occurs (window varies from minutes to >24h depending on agent)
- WHO-recommended dose: 30 mg/kg IV bolus, then 8 mg/kg/hr infusion for 24-48 hours
- Continue while monitoring AChE levels
- Despite theoretical benefit, current evidence is inadequate to show reduced mortality - the 2026 umbrella review (PMID: 42258859) confirms oximes show "neither benefit nor harm"
- Not recommended for asymptomatic patients or confirmed carbamate exposures with minimal symptoms
5. Benzodiazepines
- For seizures and agitation; titrate as needed
FMT (Fecal Microbiota Transplantation) in OP Poisoning
Short answer: There is no established role for FMT in OP poisoning.
FMT works by restoring gut microbial diversity - it is currently approved/evidence-based only for:
- Recurrent Clostridioides difficile infection (>90% efficacy, AGA-recommended for ≥2 recurrences)
- Investigational use in UC, Crohn's, hepatic encephalopathy, sepsis-related dysbiosis
Rationale for why FMT has been explored in critical illness: OP poisoning causes massive GI disruption (profuse diarrhea, vomiting, ileus), ICU stays, prolonged antibiotics, and enteral feeding disruption - all of which cause gut dysbiosis. The theoretical basis for FMT in OP poisoning would be to restore microbial balance post-acute phase, potentially reducing:
- Secondary infection risk
- Intestinal permeability
- Systemic inflammatory burden
However, searching both the medical library (Tintinalli's, Rosen's, Goodman & Gilman, Cecil Medicine) and PubMed (2021-2026) found zero published studies examining FMT specifically in OP poisoning. No clinical trials are currently registered for this indication.
The Sabiston Surgery textbook does reference FMT in sepsis (citing Keskey et al., Transl Res 2020 and Cibulkova et al., Biomolecules 2021 for FMT in critically ill patients), but none specific to OP toxicity.
Bottom line: FMT remains investigational even in general critical illness and sepsis. There is no evidence base - preclinical or clinical - for FMT specifically in OP poisoning. Management remains decontamination + atropine + supportive care ± pralidoxime.
Summary Table
| Intervention | Evidence | Notes |
|---|---|---|
| Atropine | Strong - mainstay | Titrate to dry secretions, not pupils |
| Pralidoxime | Weak (no mortality benefit proven) | Use early, before aging |
| Benzodiazepines | Standard | Seizure control |
| Rocuronium (RSI) | Preferred over succinylcholine | Avoids prolonged paralysis |
| Activated charcoal / lavage | Not recommended | No benefit, possible harm |
| Magnesium sulfate, lipid emulsion, hemoperfusion | Very low-quality evidence | Not routinely recommended (2026 umbrella review) |
| FMT | No evidence | Not an established intervention for OP poisoning |
Key reference: Chauhan V et al., "Therapeutic Interventions in Organophosphate Poisoning: An Umbrella Review of Systematic Reviews," West J Emerg Med 2026 (PMID: 42258859). Atropine remains the mainstay; evidence against routine use of most adjuvants.
This is a shared conversation. Sign in to Orris to start your own chat.